

Andrea M Pesch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7290137/publications.pdf>

Version: 2024-02-01

11
papers

188
citations

1478280

6
h-index

1281743

11
g-index

12
all docs

12
docs citations

12
times ranked

229
citing authors

#	ARTICLE	IF	CITATIONS
1	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. <i>Journal of Clinical Investigation</i> , 2020, 130, 958-973.	3.9	53
2	PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2063-2073.	1.9	38
3	Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 6568-6580.	3.2	30
4	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 35.	1.5	24
5	A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 686-696.	0.4	11
6	RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes. <i>JCI Insight</i> , 2022, 7, .	2.3	9
7	Role of Vitamins A and D in BCR-ABL Arf Acute Lymphoblastic Leukemia. <i>Scientific Reports</i> , 2020, 10, 2359.	1.6	8
8	Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. <i>Npj Breast Cancer</i> , 2022, 8, 31.	2.3	7
9	Modulating the Radiation Response for Improved Outcomes in Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 245-264.	1.5	4
10	Bcl-xL Inhibition Radiosensitizes PIK3CA/PTEN Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression. <i>Cancer Research Communications</i> , 2022, 2, 679-693.	0.7	3
11	Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. <i>British Journal of Cancer</i> , 2022, 127, 927-936.	2.9	1